Nodular lymphocyte predominant Hodgkin lymphoma: Advances in disease biology, risk stratification and treatment
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial